MetaCap

Ocular Therapeutix (OCUL) vs OPKO Health (OPK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

OPKO Health (OPK) has outperformed Ocular Therapeutix (OCUL) over the past year, gaining 18.9% versus a loss of 54.5%. Over five years, OCUL leads with a -14.8% price change compared with -62.0% for OPK. Ocular Therapeutix is the larger company by market cap ($1.23 billion vs $1.17 billion), about 1.1 times the size, while OPKO Health is growing revenue faster (-14.9% vs -18.5%).

OPKO Health converts more of its revenue into profit, with a net margin of -37.2% versus -511.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

OCUL-54.49%OPK+18.94%
+39%-10%-59%
Nov 21, 20251 yearNov 20, 2026
OCUL-16.74%OPK-63.91%
+127%+19%-89%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

OCUL versus OPK key metrics
MetricOCULOPK
Share price$5.57$1.57
Market cap$1.23B$1.17B
1-day change-4.95%-2.48%
YTD return-54.12%+24.60%
1-year return-54.49%+18.94%
5-year return-14.83%-61.99%
EPS (TTM)$-1.44$-0.16
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$51.95M$606.88M
Revenue growth (YoY)-18.47%-14.90%
Net income (latest FY)$-265.94M$-225.68M
Gross margin87.35%33.93%
Operating margin-519.75%-19.35%
Net margin-511.90%-37.19%
52-week high$16.44$1.86
52-week low$5.54$0.98
Distance from 52-week high-66.12%-15.59%
Analyst consensusstrong_buybuy
Avg. price target upside+361.94%+164.33%
Average volume3.03M3.83M
Shares outstanding220.02M742.51M
Employees3252,275
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OPK has outperformed OCUL by 73.4 percentage points over the past year.
  • OPKO Health is more profitable, keeping -37.2 cents of every revenue dollar as net income versus -511.9 cents for Ocular Therapeutix.

About Ocular Therapeutix

OCUL stock →

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 325 employees

About OPKO Health

OPK stock →

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 2,275 employees

OCUL vs OPK FAQ

Which is bigger, Ocular Therapeutix or OPKO Health?

Ocular Therapeutix (OCUL) is larger, with a market capitalization of $1.23B compared with $1.17B for OPKO Health (OPK).

Which stock has performed better over the past year, OCUL or OPK?

OPK returned +18.94% over the past 12 months, compared with -54.49% for OCUL (price return, excluding dividends). Past performance does not predict future results.

Are Ocular Therapeutix and OPKO Health in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons